Debiopharm Announces Marketing Agreement for Trelstar in Canada

Debiopharm S.A., the independent drug-development company specialising in oncology, endocrinology and niche products, is pleased to acknowledge a new marketing and supply agreement between Paladin Labs, a leading Canadian specialty pharmaceutical company and Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. (Watson) to market Trelstar 3.75 mg and Trelstar LA 11.25 mg (triptorelin pamoate for injectable suspension) in Canada. Debiopharm developed both products and was responsible for submitting the registration file to the U.S. Food and Drug Administration (FDA) and to Health Canada, the Canadian health authorities.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=238529&categoryid=10)